botulinum toxin A

What the FDA Data Shows for botulinum toxin A

The FDA label for botulinum toxin A (sold under brand names such as Botox) classifies it as a prescription-only medication in the Neuromuscular Blocker class. Botox can treat overactive bladder with symptoms like needing to go often, feeling a strong urge, and leaking urine. Official labeling lists 15 commonly reported side effects, including Urinary tract infection, Pain when urinating, Inability to fully empty the bladder.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.